CARDIOVASCULAR JOURNAL OF AFRICA • Vol 21, No 4, July/August 2010
AFRICA
205
2003;
26
(11): 3195–3196.
16. SAS 8.2. Cary NC: SAS Institute Inc, 2003.
17. Hillege HL, Janssen WM, Bak AA, Diercks GF, Grobbee DE, Crijns
HJ,
et al
; Prevend Study Group. Microalbuminuria is common, also in a
nondiabetic, nonhypertensive population, and an independent indicator
of cardiovascular risk factors and cardiovascular morbidity
. J Intern Med
2001;
249
(6): 519–526.
18. Garg AX, Kiberd BA, Clark WF, Haynes RB, Clase CM. Albuminuria
and renal insufficiency prevalence guides population screening: results
from the NHANES III
. Kidney Int
2002;
61
(6): 2165–2175.
19. Bramlage P, Wittchen HU, Pittrow D, Dikow R, Kirch W, Lehnert H,
Ritz E. [Diabetes, hypertension and microalbuminuria in primary care].
Fortschr Med Orig
2003.
121
( Suppl 1): 33–38.
20. Parving HH, Lewis JB, Ravid M, Remuzzi G, Hunsicker LG; DEMAND.
Prevalence and risk factors for microalbuminuria in a referred cohort of
type II diabetic patients: a global perspective
. Kidney Int
2006;
69
(11):
2057–2063.
21. Bramlage P, Pittrow D, Lehnert H, Höfler M, Kirch W, Ritz E, Wittchen
HU. Frequency of albuminuria in primary care: a cross sectional study.
Eur J Cardiovasc Prev Rehabil
2007;
14
(1): 107–113.
22. Gatzka CD, Reid CM, Lux A, Dart AM, Jennings GL. Left ventricular
mass and microalbuminuria: relation to ambulatory blood pressure.
Hypertension Diagnostic Service Investigators
.
Clin Exp Pharmacol
Physiol
1999;
26
(7): 514–516.
23. Summerson JH, Bell RA, Konen JC. Racial differences in the prevalence
of microalbuminuria in hypertension.
Am J Kidney Dis
1995;
26
(4):
577–579.
24. Gould MM, Mohamed-Ali V, Goubet SA, Yudkin JS, Haines AP.
Microalbuminuria: associations with height and sex in non-diabetic
subjects.
Br Med J
1993;
306
(6872): 240–242.
25. Damsgaard EM, Frøland A, Jørgensen OD, Mogensen CE.
Microalbuminuria as predictor of increased mortality in elderly people
.
Br Med J
1990;
300
(6720): 297–300.
26. Viberti GC, Hill RD, Jarrett RJ, Argyropoulos A, Mahmud U, Keen
H. Microalbuminuria as a predictor of clinical nephropathy in insulin-
dependent diabetes mellitus.
Lancet
1982;
1
(8287): 1430–1432.
27. Valensi P, Assayag M, Busby M, Pariès J, Lormeau B, Attali JR.
Microalbuminuria in obese patients with or without hypertension
.
Int J
Obes Relat Metab Disord
1996;
20
(6): 574–579.
28. Cirillo M, Senigalliesi L, Laurenzi M, Alfieri R, Stamler J, Stamler R,
et
al.
Microalbuminuria in nondiabetic adults: relation of blood pressure,
body mass index, plasma cholesterol levels, and smoking: The Gubbio
Population study.
Arch Intern Med
1998;
158
(17): 1933–1939.
29. Mykkänen L, Zaccaro DJ, Wagenknecht LE, Robbins DC, Gabriel M,
Haffner SM. Microalbuminuria is associated with insulin resistance
in nondiabetic subjects: the insulin resistance atherosclerosis study
.
Diabetes
1998;
47
(5): 793–800.
30. Wachtell K, Palmieri V, Olsen MH, Bella JN, Aalto T, Dahlöf B,
et al
.
Urine albumin/creatinine ratio and echocardiographic left ventricular
structure and function in hypertensive patients with electrocardiographic
left ventricular hypertrophy: the LIFE study. Losartan Intervention For
Endpoint Reduction.
Am Heart J
2002;
143
(2): 319–326.
31. Liu JE, Robbins DC, Palmieri V, Bella JN, Roman MJ, Fabsitz R,
et al
.
Association of albuminuria with systolic and diastolic left ventricular
dysfunction in type 2 diabetes: the Strong Heart Study.
J Am Coll
Cardiol
2003;
41
(11): 2022–2028.
32. Barzilay JI, Kronmal RA, Gottdiener JS, Smith NL, Burke GL, Tracy R,
et al
. The relationship of cardiovascular risk factors to microalbuminuria
in older adults with or without diabetes mellitus or hypertension: the
cardiovascular health study.
Am J Kidney Dis
2004;
44
(1): 25–34.
33. Fredrickson SK, Ferro TK, Schutrumpf AC. Disappearance of micro-
albuminuria in a patient with type 2 diabetes and the metabolic
syndrome in the setting of an intense exercise and dietary program with
sustained weight reduction
. Diabetes Care
2004;
27
(7): 1754–1755.
34. Lewis EJ, Hunsicker LG, Clarke WR, Berl T, Pohl MA, Lewis JB,
et al
;
Collaborative Study Group. Renoprotective effect of the angiotensin-
receptor antagonist irbesartan in patients with nephropathy due to type 2
diabetes
. N Engl J Med
2001;
345
(12): 851–860.
35. Parving HH, Lehnert H, Bröchner-Mortensen J, Gomis R, Andersen
S, Arner P; Irbesartan in Patients with Type 2 Diabetes and
Microalbuminuria Study Group. The effect of irbesartan on the develop-
ment of diabetic nephropathy in patients with type 2 diabetes
. N Engl J
Med
2001;
345
(12): 870–878.
36. Ibsen H, Olsen MH, Wachtell K, Borch-Johnsen K, Lindholm LH,
Mogensen CE,
et al
. Reduction in albuminuria translates to reduction
in cardiovascular events in hypertensive patients: losartan intervention
for endpoint reduction in hypertension study
. Hypertension
2005;
45
(2):
198–202.
37. Asselbergs FW, Diercks GF, Hillege HL, van Boven AJ, Janssen WM,
Voors AA,
et al
; Prevention of Renal and Vascular Endstage Disease
Intervention Trial (PREVEND IT) Investigators. Effects of fosinopril
and pravastatin on cardiovascular events in subjects with microalbu-
minuria
. Circulation
2004;
110
(18): 2809–2916.
38. Kalter-Leibovici O, Van Dyk DJ, Leibovici L, Loya N, Erman A, Kremer
I,
et al
. Risk factors for development of diabetic nephropathy and retin-
opathy in Jewish IDDM patients
. Diabetes
1991;
40
(2): 204–210.
39. Coresh J, Astor BC, Greene T, Eknoyan G, Levey AS. Prevalence of
chronic kidney disease and decreased kidney function in the adult US
population: Third National Health and Nutrition Examination Survey
.
Am J Kidney Dis
2003;
41
(1): 1–12.
